Aldrich; cat #M5655-1G) assay according to the manufacturer's instructions [24] [25] [26] . In brief, 1 3 9 cells (6×10 3 cells in 100µL full media, per well) were seeded in 3 different 96-well culture plates 1 4 0 (one for every time point: 24h, 48h and 72h) and incubated overnight at 37 and 5% CO 2 . Wells 1 4 1 were randomly distributed across different treatment conditions -3 wells/condition (Control: proliferation was presented as an optical density (OD) ratio of the treated to the untreated cells 1 4 9 9 sterile 200µL pipet was used to create two scratches per well in each monolayer. Cells were then 1 7 0 washed twice with dulbecco's phosphate buffered saline (D-PBS) (Sigma-Aldrich; cat #D8537-1 7 1 500ML) to remove cell debris. The remaining cells were distributed into three conditions:
Control (Full media), Vehicle (full media + 0.1% DMSO), and treatment (25µM TDG in full 1 7 3 media). Pictures of the scratches were taken using an inverted light microscope at the following 1 7 4 time points: 0h, 6h, 12h, 24h, and 48h. The distance travelled by the cells was measured using 1 7 5
Zen Microscope Software (Zen 2.3). The sphere formation assay was used as previously reported by our lab [19, 20] . In brief, Sciences; cat #354230) was allowed to solidify for 1 hour at 37°C in a humidified incubator. Wells were randomly assigned to control and treatment conditions (control, 0.1µM, 1µM, and 1 8 5 5µM TDG). 500 µL/well of complete media (+5% FBS) was gently added to the center of each 1 8 6 well and changed regularly every 3 days. At day 9 after plating, spheres were pictured and 1 8 7 counted. SH-SY5Y spheres were further harvested for propagation. For spheres propagation, the medium was aspirated from the center of the wells. The Matrigel™ was digested with 0.5mL of 1mg/mL Dispase II solution (ThermoFisher; cat #17105-1 9 1 041) dissolved in serum-free DMEM Ham's F-12 for 60 minutes at 37°C in a humidified 1 9 2 1 0 incubator. SH-SY5Y and SK-N-SH spheres were collected and incubated in warm trypsin at 1 9 3 37°C for 5 minutes; trypsin was used to dissociate spheres into single cell suspensions. Cells 1 9 4 were counted and re-seeded at 2×10 3 cells/well. The propagation of the spheres was repeated 1 9 5 over 4 generations. The sphere forming unit (SFU) was calculated as the ratio of the number of 1 9 6 spheres counted at day 9 to the number of cells originally seeded. Bright field images of the 1 9 7 spheres were obtained using Axiovert microscope from Zeiss at 5× magnification. For 2D, SH-SY5Y cells were cultured in 6-well plates (5×10 5 cells/well) until they 2 0 2 reached 70% confluency. Three wells were then treated with 25µM TDG for 48 hours, while the 2 0 3 remaining wells were taken as control. The plates were then washed with ice-cold D-PBS to 2 0 4 remove any residual media. Similarly, for 3D, SH-SY5Y spheres (G1) were treated with 5µM 2 0 5 TDG while others were taken as control. G1 spheres were collected and washed with ice-cold D- protease and phosphatase inhibitors (one tablet of each in 10mL buffer, Roche, Germany)), 2 1 0 scraped off the plates, transferred into micro-centrifuge tubes and incubated on ice for 30 2 1 1 minutes. Sonication was used to maximize the protein yield. Lysates were then centrifuged at 2 1 2 13,600 rpm for 15 minutes at 4°C, to pellet the cell debris. Protein concentrations of the collected supernatants were quantified using DC™ Protein Assay (Bio-Rad). For immunoblotting, 50μg of proteins were electrophoresed in 8% or 12% 2 1 6 polyacrylamide gel and then transferred to PVDF membranes (Bio-Rad Laboratory, CA, USA) 2 1 7 overnight. Membranes were blocked with 5% bovine serum albumin (BSA) (v/v) (Amresco; cat 2 1 8 #0332-100G) for 2 hours and blotted at 4°C overnight with primary antibodies as follows: rabbit 2 1 9
anti-phospho-GSK-3β (Ser9) (5B3) (1/500 dilution; Cell Signaling; cat #9323), rabbit anti-GSK-2 2 0 3β (1/1000 dilution; Cell Signaling; cat #27C10,), and mouse anti-GAPDH (1/5000 dilution; 2 2 1 Novus Biologicals; cat #NB300-221). The next day, membranes were washed and incubated at 2 2 2 room temperature for 2 hours with the appropriate HRP-conjugated secondary antibodies as 2 2 3 follows: mouse anti-rabbit (1/1000 dilution; Santa Cruz; cat #sc-2357) and mouse IgGκ BP (1/1000 dilution; Santa Cruz; cat #sc-516102). Finally, bands were detected using Lumi-Light 2 2 5
Western Blotting Substrate (Roche; cat #12015200001) and visualized using autoradiography. Band intensities were digitized and analyzed using ImageJ software. This study was approved by the Institutional Animal Care and Utilization Committee 2 3 1 (IACUC) of the American University of Beirut. Neuroblastoma xenografts were generated using 2 3 2 mouse SH-SY5Y cells. Cells were injected at a concentration of 1.2×10 6 cells in 100μL total 2 3 3 volume of cells and Matrigel TM (1:1) using a 27 G needle subcutaneously, into the flanks of 2 3 4 NOD-SCID male mice (6-8 weeks old) [28] . Once palpable tumor (approximate size 1mm 3 ) was 2 3 5 detected, mice were intraperitoneally injected 3 times a week for 2 weeks with 20mg/kg TDG or sacrifice. The following formula for volume assessment was applied: V = (3.14/6)×L×W×H;
where V is the tumor volume in mm 3 , L is the tumor length in mm, W is the tumor width in mm, 2 4 1 and H is the tumor height in mm. Measurements were carried out until the termination of the 2 4 2 experiment. Data represent an average of n=3 mice. The data are reported as mean ± SEM. the data was determined using proper statistical tests, including the student t-test and the two- way ANOVA statistical test, followed by multiple comparisons using Bonferroni post-hoc 2 4 9 analysis. P-values of p<0.05 (*), p<0.01 (**) and p<0.001 (***) were labeled significant, highly 2 5 0 significant and very highly significant, respectively. In our study, we first aimed to assess the expression pattern of GSK-3β gene in human 2 5 7 neuroblastoma tumor tissues as compared to other body cancer tissues. For this, we surveyed a independent t-test, p<0.001, Supp Fig 3A) and 80% for SK-N-SH cells (student independent t-3 1 7 test, p<0.001, Supp Fig 3B) . For SH-SY5Y cells, we decided to test the self-renewal ability of the cells by propagating 3 2 0 the same spheres, into two new conditions: control and treated. We noticed that after a single 3 2 1 exposure to treated conditions at G1, the SFU significantly dropped to 1.13% compared to 6.21% 3 2 2 in control conditions (student independent t-test, p<0.0001) (Fig 5) . However, once propagated 4.73% at G2). According to our data, it takes two treatment regimens in two generations to 3 2 5 completely abolish the self-renewal ability of the spheres, i.e. single cell suspensions from 3 2 6 spheres previously treated in two generations fail to form any more spheres after propagation 3 2 7 (Fig 5) . To validate the direct effect of TDG on its respective target GSK-3β, we used western 3 3 2 blotting in order to detect differences in protein expression between the cellular lysates of treated compared to the control group (Supp Fig 4A) , signifying GSK-3β inhibition. Besides, treating 3 3 8 SH-SY5Y G1 spheres with TDG significantly increased the expression of p-GSK-3β (Ser 9) by 3 3 9 around 1.15 times (p=0.0445) as compared to the control group (Supp Fig 4B) . Lastly, we assessed the potential effect of TDG on neuroblastoma tumor growth in vivo.
4 4
We injected NOD SCID mice with SH-SY5Y cells subcutaneously generating neuroblastoma 3 4 5 xenografts. The average weight of the mice was monitored throughout the experiment and was 3 4 6 maintained within a normal range during the study, signifying that TDG treatment was well 3 4 7 tolerated (Fig 6A) . Treatment with TDG (20mg/kg TDG) resulted in significant inhibition of 3 4 8 tumor growth in SH-SY5Y injected mice which was reflected by the reduction in the volume of 3 4 9 tumors after 15 days of treatment (Fig 6B) . These results indicate that TDG significantly reduces Neuroblastoma is a solid tumor of the peripheral nervous system that arises from neural 3 5 5 crest cells and is typically localized within the medulla of suprarenal glands or within the 3 5 6 sympathetic nerve ganglia [3] . The standard care of treatment for most nervous system tumors behind the failure of conventional chemotherapy is hypothesized to be the presence of dormant Molecular alteration in different signaling pathways of CSCs have been linked to 3 6 7 abnormal proliferation, self-renewal and differentiation of these cells, and accordingly many of Interestingly, GSK-3β represents a signaling node at the crossroads of many of those pathways 3 7 2 [12, 20, 39] . This molecule has been associated with several pathological processes in the human In oncology, GSK-3β has shown to express opposite actions in different tumors; it has 3 7 7 been an oncogenic molecule in some tumors, but a tumor suppressor in others [41] . The exact 3 7 8 underlying mechanism of action, at cellular and molecular levels, of GSK-3β in the context of 3 7 9 boosting tumor progression is not fully understood; yet, it has been related to blockade of GSK-3 8 0 3β-mediated upregulation of NF-κB-mediated gene transcription [14] . Hence, we hypothesized 3 8 1 that targeting this molecule with selective inhibitors, such as TDG -which is now under Phase II potential CSCs-targeted therapy to patients suffering from neuroblastoma tumor [15, 42] . neuroblastoma tissues relative to other tumor tissues, with a fold change of 1.639 (p = 4.06E-4). Next, we assessed the anti-tumor properties and mechanism of action of TDG -an in-3 9 2 clinical-trial drug that specifically inhibits GSK-3β -on two human neuroblastoma cells, SH- Eventually, we also sought to determine the ability of TDG to target the sub-population 4 0 2 of cancer stem/progenitor cells in SH-SY5Y cells using a 3D neurospheres formation assay in TDG is effective in targeting the self-renewal ability of CSCs, a hall mark of cancer progression. When compared to 2D culture, TDG treatment was more potent when used in a 3D culture, Lastly, we believe that our study has some limitations related to the methodology and 4 1 7 experimental design. First, we assessed in our work the inhibitory effect of TDG on two human 4 1 8 neuroblastoma cell lines as models for this nervous system tumor. Future experiments will 4 1 9 follow after acquiring more human cell line models for neuroblastoma to assess the inhibitory 4 2 0 effect of TDG using different cell lines. Second, in our study, we mainly relied on experimental 4 2 1 assays that serve as functional reporters of the progenitor activity of neuroblastoma cell lines, as for Alzheimer's disease, it is thus worthy of consideration in nervous system tumors as well such 4 2 7
as neuroblastoma, especially that we proved in our current study its efficiency in targeting the 4 2 8 CSC population in this tumor type. In conclusion, TDG proved to be an effective in vitro and in vivo treatment for 4 3 3 neuroblastoma cell lines and may hence serve as a potential adjuvant therapeutic agent for this 4 3 4
aggressive nervous system tumor. Henceforth, our study supports the notion that targeting GSK- Clinicians, 70 (2020) 7-30. Neuroblastoma, J Clin Oncol, 33 (2015) 3008-3017. [41] C.N. Mills, S. Nowsheen, J.A. Bonner, E.S. Yang, Emerging roles of glycogen synthase 5 6 0 kinase 3 in the treatment of brain tumors, Frontiers in molecular neuroscience, 4 (2011) 47. Oncotarget, 9 (2018) 33549-33561. 
